Affiliation:
1. School of Behavioral Sciences and Education, Penn State University, Harrisburg, Middletown, PA 17057, USA
Abstract
Substance use self-stigma is a barrier to treatment and can negatively impact individuals’ well-being and treatment engagement. Given the mixed findings in previous research and the limited specific investigation into the concept of self-stigma within the context of opioid misuse, examining factors associated with self-stigma in the context of opioid use disorder (OUD) is warranted. The current study examines the influence of individual-level factors (race, sex, urban/rural status, support group attendance) on self-stigma and willingness to disclose opioid use. Data for this study were from a larger study of OUD-related stigma among adults in Pennsylvania, U.S. The current study included participants who indicated a personal past or current history with OUD were included (n = 84). Exploratory factor analysis and multiple indicators, multiple causes (MIMIC) model were used to explore the associations between demographic factors (i.e., sex, age, race/ethnicity, urban/rural status), attendance at mutual support groups, and self-stigma factors. Results indicated that sex and attendance at mutual support groups significantly predicted levels of self-stigma. Women and individuals with no previous experience attending mutual support groups endorsed lower levels of self-stigma. Additionally, attendance at mutual support groups predicted willingness to self-disclose past and present opioid use. Individuals who reported no history of attending mutual support groups demonstrated less willingness to disclose past and present OUD use compared to participants who were support group attendees. The current research findings enhance the understanding of OUD-related self-stigma by examining its relationship with individual-level factors, disclosure, and attendance to mutual support groups. The results offer insights into the influence of sex and support group attendance on self-stigma and disclosure. These findings have significant clinical implications for developing future interventions and promoting health policy changes.
Funder
Commonwealth of Pennsylvania’s Department of Drug and Alcohol Programs
Reference69 articles.
1. CDC (2024, May 23). Provisional Data Shows U.S. Drug Overdose Deaths Top 100,000 in 2022 | Blogs, Available online: https://blogs.cdc.gov/nchs/2023/05/18/7365/.
2. A Brief History of the Opioid Epidemic and Strategies for Pain Medicine;Jones;Pain. Ther.,2018
3. The Prescription Opioid and Heroin Crisis: A Public Health Approach to An Epidemic of Addiction;Kolodny;Annu. Rev. Public Health,2015
4. Substance Abuse and Mental Health Services Administration (SAMHSA) (2024, May 23). Key Substance Use and Mental Health Indicators in The United States: Results from the 2022 National Survey on Drug Use and Health (HHS Publication No. PEP23-07-01-006, NSDUH Series H-58). Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration, Available online: https://www.samhsa.gov/data/report/2022-nsduh-annual-national-report.
5. An Investigation of Stigma in Individuals Receiving Treatment for Substance Abuse;Luoma;Addict. Behav.,2007